Trial Profile
A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 in Combination With Tremelimumab Therapy Versus Standard of Care Platinum-Based Chemotherapy in First-Line Treatment of Patients With Advanced or Metastatic Non Small-Cell Lung Cancer (NSCLC).
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 16 Feb 2024
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Tremelimumab (Primary) ; Carboplatin; Cisplatin; Gemcitabine; Paclitaxel; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Acronyms NEPTUNE
- Sponsors AstraZeneca
- 13 Feb 2024 Planned End Date changed from 29 Dec 2023 to 31 Dec 2024.
- 01 Apr 2023 Results of prespecified exploratory analysis (extended cohort enrolled in China) assessing efficacy and safety of durvalumab plus tremelimumab in patients with metastatic non-small-cell lung cancer, published in the Lung Cancer.
- 04 Jan 2023 Planned End Date changed from 30 Dec 2022 to 29 Dec 2023.